In fiscal 2026, which ended Mar 28, 2026, Haemonetics Corporation reported revenue of $1.3 billion, down 2.0% from the year before. Net income was $97.3 million, a profit margin of 7.3%. Operating income came to $156.7 million, an operating margin of 11.7%. Diluted earnings per share were $2.05. Over the twelve months ended Sep 26, 2026, revenue was $1.4 billion and net income was $103.9 million. Across the 8 fiscal years shown, revenue grew from $967.6 million in fiscal 2019 to $1.3 billion in fiscal 2026, about 4.7% a year.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.
| Line |
FY 2027
Sep 26, 2026
|
FY 2026
Mar 28, 2026
|
FY 2025
Mar 29, 2025
|
FY 2024
Mar 30, 2024
|
FY 2023
Apr 1, 2023
|
FY 2022
Apr 2, 2022
|
FY 2021
Apr 3, 2021
|
FY 2020
Mar 28, 2020
|
FY 2019
Mar 30, 2019
|
FY 2018
Mar 31, 2018
|
FY 2017
Apr 1, 2017
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1,382
+4.1%
|
1,334
-2.0%
|
1,361
+4.0%
|
1,309
+12.0%
|
1,169
+17.7%
|
993
+14.1%
|
870
-11.9%
|
988
+2.2%
|
968
|
—
|
—
|
| Cost of revenue |
558
+0.7%
|
546
-10.7%
|
612
-0.9%
|
618
+11.6%
|
554
+13.5%
|
488
+3.2%
|
473
-6.2%
|
504
-8.4%
|
550
+11.8%
|
492
-3.1%
|
508
+0.9%
|
| Gross profit |
824
+6.6%
|
788
+5.2%
|
749
+8.3%
|
692
+12.4%
|
615
+21.7%
|
506
+27.1%
|
398
-17.9%
|
485
+16.0%
|
418
+1.4%
|
412
+8.8%
|
378
-6.8%
|
| Research and development |
62
-5.2%
|
60
-4.7%
|
63
+15.2%
|
54
+8.6%
|
50
+7.1%
|
47
+42.4%
|
33
+6.4%
|
31
-13.5%
|
36
-9.0%
|
39
+4.5%
|
38
-16.5%
|
| Selling, general and administrative |
467
+7.7%
|
442
+1.3%
|
437
+1.6%
|
430
+14.1%
|
377
+10.7%
|
340
+23.6%
|
275
-2.4%
|
282
+3.1%
|
273
-13.6%
|
317
+4.9%
|
302
-4.9%
|
| Restructuring and impairment |
4
-37.8%
|
3
-77.6%
|
14
-1.2%
|
14
+2044.4%
|
1
-84.5%
|
4
+192.9%
|
1
-59.8%
|
4
+809.1%
|
0
-98.7%
|
31
+39.8%
|
22
-5.3%
|
| Operating income |
177
-27.1%
|
157
-29.3%
|
222
+34.5%
|
165
+5.7%
|
156
+93.2%
|
81
-10.0%
|
90
-13.2%
|
103
+23.7%
|
84
+48.8%
|
56
+389.8%
|
-19
+55.9%
|
| Other non-operating income (expense) |
-35
-36.4%
|
-29
-194.5%
|
-10
+25.1%
|
-13
+11.0%
|
-15
+14.5%
|
-17
-1.7%
|
-17
-3.9%
|
-16
-63.4%
|
-10
-119.0%
|
-5
+44.1%
|
-8
+14.6%
|
| Pretax income |
142
-34.6%
|
128
-39.6%
|
212
+39.6%
|
152
+7.4%
|
141
+122.2%
|
64
-12.7%
|
73
-16.3%
|
87
+18.4%
|
74
+23.5%
|
60
+317.0%
|
-27
+48.6%
|
| Income tax |
38
-22.1%
|
31
-30.8%
|
44
+29.4%
|
34
+31.9%
|
26
+28.4%
|
20
+408.9%
|
-7
-161.7%
|
11
-42.9%
|
19
+32.4%
|
14
+1263.9%
|
-1
-155.8%
|
| Net income |
104
-38.2%
|
97
-42.0%
|
168
+42.6%
|
118
+1.9%
|
115
+166.1%
|
43
-45.4%
|
79
+3.8%
|
77
+39.1%
|
55
+20.7%
|
46
+273.5%
|
-26
+52.7%
|
| Basic EPS |
2.26
-34.4%
|
2.06
-38.1%
|
3.33
+43.5%
|
2.32
+2.2%
|
2.27
+167.1%
|
0.85
-45.9%
|
1.57
+4.0%
|
1.51
+41.1%
|
1.07
+24.4%
|
0.86
+268.6%
|
-0.51
+53.2%
|
| Diluted EPS |
2.24
-34.7%
|
2.05
-38.1%
|
3.31
+44.5%
|
2.29
+2.2%
|
2.24
+166.7%
|
0.84
-45.8%
|
1.55
+4.7%
|
1.48
+42.3%
|
1.04
+22.4%
|
0.85
+266.7%
|
-0.51
+53.2%
|
| Weighted average shares, basic |
46
-5.8%
|
47
-6.3%
|
50
-0.7%
|
51
-0.2%
|
51
-0.5%
|
51
+0.7%
|
51
-0.0%
|
51
-1.6%
|
52
-2.3%
|
53
+2.4%
|
52
+1.2%
|
| Weighted average shares, diluted |
46
-5.4%
|
47
-6.7%
|
51
-1.3%
|
51
-0.0%
|
51
+0.1%
|
51
+0.1%
|
51
-1.0%
|
52
-2.1%
|
53
-1.0%
|
54
+3.8%
|
52
+1.2%
|
| Other measures | |||||||||||
| Depreciation and amortization |
110
-4.1%
|
112
-3.3%
|
116
+18.9%
|
97
+4.2%
|
93
-4.5%
|
98
+16.0%
|
84
-23.6%
|
110
+0.8%
|
109
+22.6%
|
89
-0.5%
|
90
-0.2%
|
| EBITDA |
287
-19.7%
|
268
-20.4%
|
337
+28.7%
|
262
+5.1%
|
249
+39.7%
|
178
+2.6%
|
174
-18.5%
|
214
+10.7%
|
193
+32.7%
|
145
+106.7%
|
70
+53.0%
|
| Margins | |||||||||||
| Gross margin |
59.63%
|
59.04%
|
55.04%
|
52.83%
|
52.63%
|
50.90%
|
45.70%
|
49.02%
|
43.15%
|
—
|
—
|
| Operating margin |
12.80%
|
11.75%
|
16.30%
|
12.60%
|
13.35%
|
8.13%
|
10.31%
|
10.46%
|
8.63%
|
—
|
—
|
| Pretax margin |
10.27%
|
9.60%
|
15.58%
|
11.60%
|
12.10%
|
6.41%
|
8.38%
|
8.82%
|
7.61%
|
—
|
—
|
| Profit margin |
7.52%
|
7.29%
|
12.32%
|
8.98%
|
9.87%
|
4.37%
|
9.13%
|
7.74%
|
5.69%
|
—
|
—
|
| EBITDA margin |
20.73%
|
20.12%
|
24.79%
|
20.02%
|
21.34%
|
17.97%
|
19.99%
|
21.61%
|
19.94%
|
—
|
—
|
| Effective tax rate |
26.83%
|
24.00%
|
20.93%
|
22.59%
|
18.39%
|
31.83%
|
-8.99%
|
12.19%
|
25.28%
|
23.58%
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- HAE (NYSE)
- Fiscal year ends
- April 3
- Incorporated in
- MA
- Headquarters
- Boston, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 313143
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.